Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 92.85B -32.4% |
| Revenue (ttm) | 46.72B +5.5% |
| Net Income | 7.81B +40.5% |
| EPS | 6.37 +43.6% |
| Shares Out | 1.21B |
| PE Ratio | 19.08 |
| Forward PE | 9.17 |
| Dividend | 4.12 (5.36%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 851,942 |
| Average Volume | 2,135,830 |
| Open | 76.52 |
| Previous Close | 76.89 |
| Day's Range | 75.33 - 76.81 |
| 52-Week Range | 74.85 - 108.86 |
| Beta | 0.36 |
| RSI | 40.50 |
| Earnings Date | Apr 23, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, COVID-19 vaccine Nuvaxovid, booster, meningitis, and travel and endemic vaccines, that in... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial StatementsNews
Mirecule Expands Strategic FSHD Collaboration with Sanofi
GAITHERSBURG, Md.--(BUSINESS WIRE)--Mirecule expands strategic collaboration with Sanofi on advancement of best-in-class ARC treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).
Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Sanofi's venglusta t earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026 . The US Food and Drug Administration (FDA) has granted Breakthrough Therapy des...
Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Sanofi's venglusta t earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026 . The US Food and Drug Administration (FDA) has granted Breakthrough Therapy desi...
Big drugmakers must face US overcharge claims on medications for low-income patients
A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds of millions of dollars by overcharging ...
The Big 3: PR, ELF, SNY
From oil, beauty, and therapeutic resource stocks, @ElliottWaveTrader's Tammy Marshall turns to three companies she sees as unsung market opportunities. The Fibonacci Princess offers insight and exa...
Sanofi: An Undervalued Stock For Long-Term Dividend Growth Investors
Sanofi has increased its dividend for 31 consecutive years. That's a fantastic track record. Sanofi increased its revenue from €34.7 billion in FY 2016 to €43.6 billion in FY 2025. That's a compound a...
Sanofi: Information concerning the total number of voting rights and shares - February 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit
Brazilian drugmaker EMS is open to fresh acquisitions to expand internationally after inking a major deal to buy Sanofi's Brazil-based generic drugmaker Medley, and is gearing up to launch its own se...
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for MGC030,...
P/E Ratio Insights for Sanofi
In the current session, Sanofi Inc. (NASDAQ: SNY) is trading at $43.87, after a 1.54% decrease. Over the past month, the stock fell by 9.80% , and in the past year, by 25.32% . With performance like ...
Sanofi (SNY) to Sell Medley to EMS in $500M+ Deal
Sanofi (SNY) to Sell Medley to EMS in $500M+ Deal
EMA Panel Backs Moderna's COVID-Flu Shot, Sanofi's Sleeping Sickness Drug, Ipsen's Cancer Drug
(RTTNews) - At its February 2026 meeting, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted positive opinions for Moderna's combined COVID-19 -Influenza vacci...
Need Growing EPS And Dividends? Prescribe Sanofi
Sanofi is deeply undervalued, trading at a 29% discount to a $65 fair value estimate, with a forward P/E of 9.2 versus a 10-year average of 13. Robust growth is driven by blockbuster drugs like Dupixe...
Press Release: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
Press Release: Filing of an amendment to the French "Document d'Enregistrement Universel" containing the Annual Financial Report
Filing of an amendment to the French "Document d'Enregistrement Universel" containing the Annual Financial Report Paris, March 4, 2026 . Sanofi announces today the filing of an amendment to its "Docum...
Press Release: Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report
Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “Docume...
Sino Biopharmaceutical (SBHMY) Strikes $1.53B Deal with Sanofi for Cancer Drug
Sino Biopharmaceutical (SBHMY) Strikes $1.53B Deal with Sanofi for Cancer Drug
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln
Hong Kong-listed Sino Biopharmaceutical said on Wednesday its unit has signed an exclusive global licensing deal with French drugmaker Sanofi worth up to $1.53 billion, giving the European pharma gi...
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
LLY, JNJ, SNY and BAYRY ride strong pipelines and M&A momentum as Large-Cap Pharma rebounds in 2026 despite pricing and patent risks.
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Sanofi's Rilzabrutinib Gets Orphan Drug Designation In Japan For IgG4-Related Disease
(RTTNews) - Sanofi (SNY, SAN.PA, SNYNF) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to Rilzabrutinib for IgG4-related disease (IgG4-RD...
Sanofi: Rilzabrutinib Granted Orphan Drug Designation In Japan For IgG4-related Disease
(RTTNews) - Sanofi (SNY, SAN.PA) announced the Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to rilzabrutinib, an oral, reversible covalent Bruton's tyrosine kina...
Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third global orphan drug desi...
Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third global orphan drug desi...
Sanofi (SNY) Showcases Promising Ayvakit Data in Systemic Mastocytosis
Sanofi (SNY) Showcases Promising Ayvakit Data in Systemic Mastocytosis